The 3 Biggest Challenges for Liquid Biopsies

Despite their revolutionary potential, blood-based cancer detection tests face significant hurdles to becoming a standard part of clinical care.

The top 3

  1. Low Sensitivity in Early Stages: Most liquid biopsy tests currently demonstrate significantly lower sensitivity for Stage I cancers compared to later-stage or metastatic disease.
  2. False Positive Risk Management: High specificity is required to avoid 'false alarms' that lead to unnecessary, invasive follow-up diagnostic procedures and increased patient anxiety.
  3. Lack of Standardized Clinical Validation: The field lacks a universal benchmark or standard, making it difficult for regulators and insurers to compare different companies' test performance metrics.

Sources

Open the full topic